FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281776986> ?p ?o ?g. }

• W4281776986 endingPage "e16204" @default.
• W4281776986 startingPage "e16204" @default.
• W4281776986 abstract "e16204 Background: A well-recognized class effect of immune check point inhibitors (ICI) is IrAEs ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI. Treatment related deaths are reported in ̃5% of patients (pts) treated with ICI. There are, however, no reliable markers to predict the onset & severity of IrAEs. We tested the association between neutrophil-lymphocyte ratio (NLR) & platelet-lymphocyte ratio (PLR) at baseline with development of clinically significant IrAE (graded ≥2) in HCC pts treated with ICI. Methods: Data was extracted from a large international database from a consortium of 11 tertiary-care referral centers located in the USA, Europe & Asia. NLR=Absolute neutrophil count/ Absolute lymphocyte count (ALC) & PLR=Platelet count/ALC. A cutoff of 5 for was used NLR & 300 for PLR based on literature. We also tested the association between antibiotic & steroid exposure to IrAEs. Results: Clinical data was collected from 361 pts treated between 2016–2020 across the USA (66%), Asia (12%) & Europe (22%) in this multinational database. Most pts received Nivolumab monotherapy (n=318, 74%). 167 (46%) pts developed at least one IrAE, highest grade 1 in 80 (48%), grade ≥2 in 87(52%) pts. Baseline characteristics did not differ significantly between the groups (Table). In a univariable regression model to predict grade ≥2 IrAEs, a PLR >300 was associated with a lower incidence of clinically significant IrAEs (OR = 0.40; p=0.044). NLR >5 was associated with a trend toward lower incidence of clinically significant IrAEs (OR = 0.58; p=0.097). Multivariate analyses confirmed PLR as independent predictive marker of grade ≥2 IrAEs (OR = 0.24; p=0.007). Antibiotics use was not associated with IrAE incidence (OR = 1.02; p=0.954). Steroid use was associated with a >2-fold higher incidence of grade ≥2 IrAEs (OR = 2.74; p<0.001), though it may be noted that 37% of pts received steroids for treatment of IrAEs. Conclusions: Lower NLR & PLR may predict the appearance of IrAEs in HCC treated with ICI, although this conclusion warrants prospective validation. This finding is in keeping with several studies that showed improved survival in pts who develop of IrAEs & have a lower NLR & PLR.[Table: see text]" @default.
• W4281776986 created "2022-06-13" @default.
• W4281776986 creator A5000475484 @default.
• W4281776986 creator A5013417150 @default.
• W4281776986 creator A5014448224 @default.
• W4281776986 creator A5031516587 @default.
• W4281776986 creator A5038563139 @default.
• W4281776986 creator A5039326252 @default.
• W4281776986 creator A5045113980 @default.
• W4281776986 creator A5046065062 @default.
• W4281776986 creator A5048681236 @default.
• W4281776986 creator A5050085113 @default.
• W4281776986 creator A5054555044 @default.
• W4281776986 creator A5059373658 @default.
• W4281776986 creator A5065803904 @default.
• W4281776986 creator A5066308492 @default.
• W4281776986 creator A5080871683 @default.
• W4281776986 creator A5082032876 @default.
• W4281776986 creator A5089529460 @default.
• W4281776986 date "2022-06-01" @default.
• W4281776986 modified "2023-10-01" @default.
• W4281776986 title "Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC)." @default.
• W4281776986 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16204" @default.
• W4281776986 hasPublicationYear "2022" @default.
• W4281776986 type Work @default.
• W4281776986 citedByCount "1" @default.
• W4281776986 countsByYear W42817769862023 @default.
• W4281776986 crossrefType "journal-article" @default.
• W4281776986 hasAuthorship W4281776986A5000475484 @default.
• W4281776986 hasAuthorship W4281776986A5013417150 @default.
• W4281776986 hasAuthorship W4281776986A5014448224 @default.
• W4281776986 hasAuthorship W4281776986A5031516587 @default.
• W4281776986 hasAuthorship W4281776986A5038563139 @default.
• W4281776986 hasAuthorship W4281776986A5039326252 @default.
• W4281776986 hasAuthorship W4281776986A5045113980 @default.
• W4281776986 hasAuthorship W4281776986A5046065062 @default.
• W4281776986 hasAuthorship W4281776986A5048681236 @default.
• W4281776986 hasAuthorship W4281776986A5050085113 @default.
• W4281776986 hasAuthorship W4281776986A5054555044 @default.
• W4281776986 hasAuthorship W4281776986A5059373658 @default.
• W4281776986 hasAuthorship W4281776986A5065803904 @default.
• W4281776986 hasAuthorship W4281776986A5066308492 @default.
• W4281776986 hasAuthorship W4281776986A5080871683 @default.
• W4281776986 hasAuthorship W4281776986A5082032876 @default.
• W4281776986 hasAuthorship W4281776986A5089529460 @default.
• W4281776986 hasConcept C120665830 @default.
• W4281776986 hasConcept C121332964 @default.
• W4281776986 hasConcept C126322002 @default.
• W4281776986 hasConcept C197934379 @default.
• W4281776986 hasConcept C2777063308 @default.
• W4281776986 hasConcept C2777761686 @default.
• W4281776986 hasConcept C2778019345 @default.
• W4281776986 hasConcept C2778715236 @default.
• W4281776986 hasConcept C2778963024 @default.
• W4281776986 hasConcept C29730261 @default.
• W4281776986 hasConcept C61511704 @default.
• W4281776986 hasConcept C71924100 @default.
• W4281776986 hasConcept C74133956 @default.
• W4281776986 hasConcept C90924648 @default.
• W4281776986 hasConceptScore W4281776986C120665830 @default.
• W4281776986 hasConceptScore W4281776986C121332964 @default.
• W4281776986 hasConceptScore W4281776986C126322002 @default.
• W4281776986 hasConceptScore W4281776986C197934379 @default.
• W4281776986 hasConceptScore W4281776986C2777063308 @default.
• W4281776986 hasConceptScore W4281776986C2777761686 @default.
• W4281776986 hasConceptScore W4281776986C2778019345 @default.
• W4281776986 hasConceptScore W4281776986C2778715236 @default.
• W4281776986 hasConceptScore W4281776986C2778963024 @default.
• W4281776986 hasConceptScore W4281776986C29730261 @default.
• W4281776986 hasConceptScore W4281776986C61511704 @default.
• W4281776986 hasConceptScore W4281776986C71924100 @default.
• W4281776986 hasConceptScore W4281776986C74133956 @default.
• W4281776986 hasConceptScore W4281776986C90924648 @default.
• W4281776986 hasIssue "16_suppl" @default.
• W4281776986 hasLocation W42817769861 @default.
• W4281776986 hasOpenAccess W4281776986 @default.
• W4281776986 hasPrimaryLocation W42817769861 @default.
• W4281776986 hasRelatedWork W2399204301 @default.
• W4281776986 hasRelatedWork W2746732551 @default.
• W4281776986 hasRelatedWork W2765432779 @default.
• W4281776986 hasRelatedWork W2791997666 @default.
• W4281776986 hasRelatedWork W2905398573 @default.
• W4281776986 hasRelatedWork W2914394780 @default.
• W4281776986 hasRelatedWork W2918103461 @default.
• W4281776986 hasRelatedWork W2924415301 @default.
• W4281776986 hasRelatedWork W4249187129 @default.
• W4281776986 hasRelatedWork W4365449243 @default.
• W4281776986 hasVolume "40" @default.
• W4281776986 isParatext "false" @default.
• W4281776986 isRetracted "false" @default.
• W4281776986 workType "article" @default.